Tuberc Respir Dis.  2015 Jul;78(3):161-167. 10.4046/trd.2015.78.3.161.

Treatment of Drug Susceptible Pulmonary Tuberculosis

• Shin HJ
• Kwon YS

• KMID: 2320638
• DOI: http://doi.org/10.4046/trd.2015.78.3.161

Abstract

Tuberculosis (TB) remains a major global health problem, and the incidence of TB cases has not significantly decreased over the past decade in Korea. The standard short course regimen is highly effective against TB, but requires multiple TB-specific drugs and a long treatment duration. Recent studies using late-generation fluoroquinolones and/or high-dose rifapentine-containing regimens to shorten the duration of TB treatment showed negative results. Extending the treatment duration may be considered in patients with cavitation on the initial chest radiograph and positivity in sputum culture at 2 months of treatment for preventing TB relapse. Current evidence does not support the use of fixed-dose combinations compared to separate drugs for the purpose of improving treatment outcomes. All patients receiving TB treatment should be monitored regularly for response to therapy, facilitation of treatment completion, and management of adverse drug reactions. Mild adverse effects can be managed with symptomatic therapy and changing the timing of the drug administration, but severe adverse effects require a discontinuation of the offending drugs.

Keyword

Tuberculosis; Antitubercular Agents; Fluoroquinolones; Combination Therapy; Drug-Related Side Effects and Adverse Reactions

MeSH Terms

Antitubercular Agents
Drug-Related Side Effects and Adverse Reactions
Fluoroquinolones
Humans
Incidence
Korea
Radiography, Thoracic
Recurrence
Sputum
Tuberculosis
Tuberculosis, Pulmonary*
Antitubercular Agents
Fluoroquinolones

Reference

1. World Health Organization. Global tuberculosis report 2014 [Internet]. Geneva: World Health Organization;2014. cited 2014 Mar 1. Available from: http://apps.who.int/iris/bitstream/10665/137094/1/9789241564809_eng.pdf.

2. Hong YP, Kim SJ, Lew WJ, Lee EK, Han YC. The seventh nationwide tuberculosis prevalence survey in Korea, 1995. Int J Tuberc Lung Dis. 1998; 2:27–36. PMID: 9562108.

3. Park YK, Park YS, Na KI, Cho EH, Shin SS, Kim HJ. Increased tuberculosis burden due to demographic transition in Korea from 2001 to 2010. Tuberc Respir Dis. 2013; 74:104–110.

4. Korea Centers for Disease Control and Prevention. Annual report on the notified tuberculosis patients in Korea 2012 [Internet]. Cheongwon: Korea Centers for Disease Control and Prevention;2013. cited 2014 Mar 1. Available from: http://tbfree.cdc.go.kr/tbfree/cmm/BoardList.do?boardType=REPORT&id=4500.

5. Park YS, Hong SJ, Boo YK, Hwang ES, Kim HJ, Cho SH, et al. The national status of tuberculosis using nationwide medical records survey of patients with tuberculosis in Korea. Tuberc Respir Dis. 2012; 73:48–55.

6. Kim HJ. Current status of tuberculosis in Korea. Korean J Med. 2012; 82:257–262.

7. Statistics Korea. Annual report of deaths by cause 2012 [Internet]. Daejeon: Statistics Korea;2013. cited 2014 Mar 1. Available from: http://kosis.kr/ups/ups_01List01.jsp?grp_no=1005&pubcode=YD&type=F.

8. Kwon YS, Kim YH, Song JU, Jeon K, Song J, Ryu YJ, et al. Risk factors for death during pulmonary tuberculosis treatment in Korea: a multicenter retrospective cohort study. J Korean Med Sci. 2014; 29:1226–1231. PMID: 25246740.

9. Zumla A, Raviglione M, Hafner R, von Reyn CF. Tuberculosis. N Engl J Med. 2013; 368:745–755. PMID: 23425167.

10. Joint Committee for the Revision of Korean Guidelines for Tuberculosis. Korea Centers for Disease Control and Prevention. Korean guidelines for tuberculosis. 2nd ed. Seoul and Cheongwon: Joint Committee for the Revision of Korean Guidelines for Tuberculosis, Korean Centers for Disease Control and Prevention;2014.

11. Kwon YS, Jeong BH, Koh WJ. Tuberculosis: clinical trials and new drug regimens. Curr Opin Pulm Med. 2014; 20:280–286. PMID: 24614239.

12. Gillespie SH, Crook AM, McHugh TD, Mendel CM, Meredith SK, Murray SR, et al. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. N Engl J Med. 2014; 371:1577–1587. PMID: 25196020.

13. Jindani A, Harrison TS, Nunn AJ, Phillips PP, Churchyard GJ, Charalambous S, et al. High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. N Engl J Med. 2014; 371:1599–1608. PMID: 25337749.

14. Merle CS, Fielding K, Sow OB, Gninafon M, Lo MB, Mthiyane T, et al. A four-month gatifloxacin-containing regimen for treating tuberculosis. N Engl J Med. 2014; 371:1588–1598. PMID: 25337748.

15. Lienhardt C, Cook SV, Burgos M, Yorke-Edwards V, Rigouts L, Anyo G, et al. Efficacy and safety of a 4-drug fixed-dose combination regimen compared with separate drugs for treatment of pulmonary tuberculosis: the Study C randomized controlled trial. JAMA. 2011; 305:1415–1423. PMID: 21486974.

16. Albanna AS, Smith BM, Cowan D, Menzies D. Fixed-dose combination antituberculosis therapy: a systematic review and meta-analysis. Eur Respir J. 2013; 42:721–732. PMID: 23314904.

17. Jo KW, Yoo JW, Hong Y, Lee JS, Lee SD, Kim WS, et al. Risk factors for 1-year relapse of pulmonary tuberculosis treated with a 6-month daily regimen. Respir Med. 2014; 108:654–659. PMID: 24518046.

18. Nunn AJ, Cook SV, Burgos M, Rigouts L, Yorke-Edwards V, Anyo G, et al. Results at 30 months of a randomised trial of FDCs and separate drugs for the treatment of tuberculosis. Int J Tuberc Lung Dis. 2014; 18:1252–1254. PMID: 25216842.

19. Seon HJ, Kim YI, Lim SC, Kim YH, Kwon YS. Clinical significance of residual lesions in chest computed tomography after anti-tuberculosis treatment. Int J Tuberc Lung Dis. 2014; 18:341–346. PMID: 24670573.

20. Shin HJ, Lee HS, Kim YI, Lim SC, Jung JP, Ko YC, et al. Hepatotoxicity of anti-tuberculosis chemotherapy in patients with liver cirrhosis. Int J Tuberc Lung Dis. 2014; 18:347–351. PMID: 24670574.

21. Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med. 2003; 167:603–662. PMID: 12588714.

22. Schlossberg D. Tuberculosis and nontuberculosis mycobacterial infections. Washington, DC: ASM Press;2011.

23. World Health Organization. Treatment of tuberculosis: guidelines for national programmes. 4th ed. Geneva: World Health Organization;2009. WHO/HTM/TB/2009.420.

24. Combs DL, O'Brien RJ, Geiter LJ. USPHS Tuberculosis Short-Course Chemotherapy Trial 21: effectiveness, toxicity, and acceptability. The report of final results. Ann Intern Med. 1990; 112:397–406. PMID: 2155569.

25. Chang KC, Leung CC, Yew WW, Ho SC, Tam CM. A nested case-control study on treatment-related risk factors for early relapse of tuberculosis. Am J Respir Crit Care Med. 2004; 170:1124–1130. PMID: 15374844.

26. Johnson JL, Hadad DJ, Dietze R, Maciel EL, Sewali B, Gitta P, et al. Shortening treatment in adults with noncavitary tuberculosis and 2-month culture conversion. Am J Respir Crit Care Med. 2009; 180:558–563. PMID: 19542476.

27. Cuneo WD, Snider DE Jr. Enhancing patient compliance with tuberculosis therapy. Clin Chest Med. 1989; 10:375–380. PMID: 2673646.

28. The promise and reality of fixed-dose combinations with rifampicin. A joint statement of the International Union Against Tuberculosis and Lung Disease and the Tuberculosis Programme of the World Health Organization. Tuber Lung Dis. 1994; 75:180–181. PMID: 7919308.

29. Blomberg B, Spinaci S, Fourie B, Laing R. The rationale for recommending fixed-dose combination tablets for treatment of tuberculosis. Bull World Health Organ. 2001; 79:61–68. PMID: 11217670.

30. Milan-Segovia RC, Dominguez-Ramirez AM, Jung-Cook H, Magana-Aquino M, Romero-Mendez MC, Medellin-Garibay SE, et al. Relative bioavailability of rifampicin in a three-drug fixed-dose combination formulation. Int J Tuberc Lung Dis. 2010; 14:1454–1460. PMID: 20937187.

31. Im JG, Itoh H, Shim YS, Lee JH, Ahn J, Han MC, et al. Pulmonary tuberculosis: CT findings--early active disease and sequential change with antituberculous therapy. Radiology. 1993; 186:653–660. PMID: 8430169.

32. Kim WS, Moon WK, Kim IO, Lee HJ, Im JG, Yeon KM, et al. Pulmonary tuberculosis in children: evaluation with CT. AJR Am J Roentgenol. 1997; 168:1005–1009. PMID: 9124105.

33. McGuinness G, Naidich DP, Jagirdar J, Leitman B, McCauley DI. High resolution CT findings in miliary lung disease. J Comput Assist Tomogr. 1992; 16:384–390. PMID: 1592920.

34. Pastores SM, Naidich DP, Aranda CP, McGuinnes G, Rom WN. Intrathoracic adenopathy associated with pulmonary tuberculosis in patients with human immunodeficiency virus infection. Chest. 1993; 103:1433–1437. PMID: 8486023.

35. Hulnick DH, Naidich DP, McCauley DI. Pleural tuberculosis evaluated by computed tomography. Radiology. 1983; 149:759–765. PMID: 6647852.

36. Lee JJ, Chong PY, Lin CB, Hsu AH, Lee CC. High resolution chest CT in patients with pulmonary tuberculosis: characteristic findings before and after antituberculous therapy. Eur J Radiol. 2008; 67:100–104. PMID: 17870275.

37. World Health Organization. Definitions and reporting framework for tuberculosis, 2013 revision: WHO/HTM/TB/2013.2 [Internet]. Geneva: World Health Organization;2013. cited 2015 Mar 3. Available from: http://apps.who.int/iris/bitstream/10665/79199/1/9789241505345_eng.pdf.

38. Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM, et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med. 2006; 174:935–952. PMID: 17021358.

39. Kang YA. Tuberculosis treatment in patients with comorbidities. Tuberc Respir Dis. 2014; 76:257–260.

40. Lee BH, Koh WJ, Choi MS, Suh GY, Chung MP, Kim H, et al. Inactive hepatitis B surface antigen carrier state and hepatotoxicity during antituberculosis chemotherapy. Chest. 2005; 127:1304–1311. PMID: 15821209.

41. Kwon YS, Koh WJ, Suh GY, Chung MP, Kim H, Kwon OJ. Hepatitis C virus infection and hepatotoxicity during antituberculosis chemotherapy. Chest. 2007; 131:803–808. PMID: 17356096.